- Coordinator
- Technische Universitaet Wien, Austria
- Runs
- 1 October 2026 to 31 March 2028
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101335615
What the project is doing
In the project's own words, from its summary on CORDIS.
Bioorthogonal click-to-release chemistry enables selective bond cleavage in complex biological environments and has emerged as a powerful concept for controlled prodrug activation, most prominently through trans-cyclooctenes and tetrazines. However, established systems face trade-offs between reaction speed, release efficiency, and stability, limiting their application in therapeutic settings. We have discovered a strained cleavable trans-cyclooctene linker that uniquely combines ultrafast click kinetics with high release efficiency and stability.
Compared to current approaches, this TCO exhibits more than 20-fold faster click reactivity, enabling activation under conditions not accessible with existing methods. This advance enables efficient prodrug activation even at nanomolar concentrations, opening new possibilities for targeted therapeutic strategies that remain out of reach. The project will establish proof of concept by developing TCO-caged prodrugs of clinically relevant therapeutics and validating this process using tetrazine triggers, including scaffolds already advanced to clinical trials.
Release kinetics, stability in biological media, and biological activity will be systematically evaluated in solution and cellular models. A central concept of the project is click accumulation, where ultrafast kinetics enable local capture and activation of circulating prodrugs. This will be demonstrated in microfluidic models that mimic vascular flow, providing evidence for efficient activation and therapeutic efficacy at low systemic concentrations.
Supported by an initial patent filing, this technology represents a versatile platform with strong translational potential. It is expected to create new opportunities for safer and more effective targeted therapeutics, with potential applications in prodrug strategies and related delivery systems.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Technische Universitaet Wien | Wien | Austria | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI